[New goals for depression therapy].
Nataliia N PetrovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2022)
The review is devoted to the consideration of the effectiveness of treatment of depression, the ratio of symptomatic and functional remission, factors associated with the achievement of high-quality remission and recovery of patients. Currently, between 29 and 66% of patients do not fully recover from antidepressant therapy and have residual symptoms of depression. Persistent depressive symptoms, neurocognitive deficits predict increased risk of relapse, social disability, impair interpersonal relationships, and represent a barrier to functional recovery. The results of a comparative analysis of antidepressants in terms of their effect on the restoration of the functioning of patients with depression are presented. It has been established that the positive impact on the social functioning of patients should be an important criterion when choosing an antidepressant for supporting therapy. Effective therapeutic approaches that maintain symptomatic remission increase the potential for functional recovery.
Keyphrases
- depressive symptoms
- end stage renal disease
- newly diagnosed
- ejection fraction
- prognostic factors
- peritoneal dialysis
- systematic review
- multiple sclerosis
- major depressive disorder
- traumatic brain injury
- stem cells
- public health
- systemic lupus erythematosus
- rheumatoid arthritis
- disease activity
- risk assessment
- cell therapy
- replacement therapy
- bone marrow
- global health
- human health